ALX Oncology Holdings Inc. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies. The company has no approved products and generates no product revenue. Its primary assets are its pipeline, led by the CD47 blocker evorpacept and the EGFR-targeted antibody-drug conjugate ALX2004.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(25.9) million | $(39.4) million | $(56.7) million | $(75.0) million |
| Net Loss Per Share | $(0.49) | $(0.76) | $(1.05) | $(1.47) |
| Research & Development Expenses | $18.0 million | $34.7 million | $41.9 million | $66.4 million |
| General & Administrative Expenses | $5.5 million | $6.9 million | $13.4 million | $12.9 million |
| Impairment Charge | $3.2 million | $0 | $3.2 million | $0 |
| Cash, Cash Equivalents & Investments | $83.5 million (as of June 30, 2025) | |||
| Term Loan Outstanding | $10.0 million (Principal) | |||
| Accumulated Deficit | $677.8 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 36% in Q2 2025 compared to Q2 2024. R&D expenses dropped 48% primarily due to reduced clinical manufacturing costs, a 30% workforce reduction (RIF) in Q1 2025, and lower stock-based compensation.
- Impairment Charge: The company recorded a $3.2 million non-cash impairment charge in Q2 2025 related to the decision to sublease its Palo Alto facility. This charge did not exist in the prior year period.
- Liquidity Position: Total cash, cash equivalents, and investments decreased from $131.3 million at year-end 2024 to $83.5 million at June 30, 2025, reflecting operational burn and investment maturities.
- Interest Income: Interest income declined 57% in Q2 2025 compared to the prior year due to lower average cash and investment balances.
Guidance, Outlook, and Risks
- Clinical Pipeline Updates:
- Evorpacept (Gastric Cancer): Updated ASPEN-06 data showed an ORR of 41.3% in the ITT population. However, the FDA indicated that a Phase 3 trial versus ENHERTU would be required for approval in the second-line setting. Consequently, ALX Oncology will not pursue a U.S. registrational path for gastric cancer and will seek partnerships.
- Evorpacept (Breast Cancer): The ASPEN-Breast study was amended to a single-arm design focusing on patients with high CD47 expression.
- Evorpacept (Colorectal Cancer): The ASPEN-CRC study was paused to streamline resources.
- ALX2004: The IND was cleared by the FDA in April 2025, with Phase 1 trials anticipated to begin in August 2025.
- Liquidity Outlook: Management believes existing capital resources ($83.5 million) are sufficient to fund operations into the first quarter of 2027. The company has an At-The-Market (ATM) offering program available and a term loan facility with $25.0 million remaining available at the lenders' discretion.
- Nasdaq Compliance Risk: The company received notice from Nasdaq on April 23, 2025, regarding non-compliance with the $1.00 minimum bid price requirement. It has a 180-day compliance period (until October 20, 2025) to regain compliance, potentially via a reverse stock split. Failure to comply could result in delisting.
- Workforce Reduction: The company recently reduced its workforce by approximately 30% to preserve cash and prioritize the pipeline.
Investor Verification Checklist
- Verify the specific terms and likelihood of securing a development partner for the gastric cancer program given the FDA's Phase 3 requirement.
- Monitor the stock price closely to assess the risk of Nasdaq delisting before the October 20, 2025 deadline.
- Confirm the timeline for the initiation of the ALX2004 Phase 1 trial (anticipated August 2025).
- Review the details of the $3.2 million impairment charge to understand the impact on future facility costs and lease obligations.
- Assess the sufficiency of the $83.5 million cash runway against the revised burn rate following the 30% workforce reduction.